RootPath Genomics, a preclinical-stage biotech firm that develops personalised immunotherapy and cell therapy for solid tumours, has raised $50 million in a Series B round.
RootPath, which has its office in the US, plans to use the financing to fund the development and commercialisation of its product pipeline, including the construction of GMP facilities in China for investigator initiated trials (IITs) and Phase I clinical trials.